comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 00:01:06 - browse：18

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Why Sanofi got shellacked over its spinoff

WSS

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Diversifying clinical trials isn't enough to close racial gaps: study

NIH nominee Bertagnolli will get October confirmation hearing

Cassava reveals details — and problems — with Alzheimer's study

Why Sanofi got shellacked over its spinoff

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

entertainment

comprehensive

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

Ethical issues complicate the benefits of medical crowdfunding

Malaria cases in Florida and Texas: Here’s what you need to know

What drug price negotiations mean for Medicare Part D

Peter Hotez and the public health issue of online harassment

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

At least 13 dead in Texas as scorching temps continue

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Virginia high school admissions case could be legal follow

Stem cell treatment guidelines are released by FDA

hotspot

Covid hospitalizations on the rise, Humana says

Snackable artificial intelligence, expert AI, and the pharma industry

Biden's order seeks to regulate AI risk without stifling innovation

Advances in CAR

Illumina names Agilent executive as new CEO

House transparency, PBM reform bill gains bipartisan support

knowledge

knowledge

focus

Wikipedia